BIO Asia-Taiwan 2021 has already held an online opening ceremony on July 21. This year’s online exhibition has more than 300 manufacturers participating, and Combating Pandemic is one of the focus themes.
Taipei, Taiwan (Merxwire) – BIO Asia-Taiwan Exhibition is the annual event for the biotechnology industry. BIO Asia-Taiwan 2021 includes exhibitions, forums, business opportunities matching, and company outlook briefings. The entire event will be held online from July 21-25. The related in-person exhibition will be held in Taipei from November 4-7.
This event has been held for the third time. A total of 17 countries and regions from the United States, Canada, Brazil, the United Kingdom, France, Germany, Switzerland, Finland, the Netherlands, Belgium, Australia, China, Japan, South Korea, Singapore, the Philippines, and Hong Kong participated.
More than 300 vendors are participating in the online exhibition this year, and more than 1,300 participants have registered for the forum. More than 500 manufacturers from Asia, South and North America, Europe, and Australia participated in one-to-one matchmaking.
This conference focused on five topics: Combating Pandemic, Advanced Therapies, Precision Medicine, Digital Health, Investment & Collaboration. Among them, Combating Pandemic is the focus of attention. COVID-19 has affected the world, and relevant discussions will help develop epidemic prevention and policy formulation.
Nobel laureate Michael Houghton and Moderna co-founder Robert Langer also participated in the speech. Michael Houghton described the progress of the COVID-19 vaccine, while Langer shared his entrepreneurial experience.
Langer said that although Moderna’s development seems to be going smoothly and has passed the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA), many scientists and the media still disagree with it. In the future, we will continue to use mRNA platform technology to develop therapies that help global human health.
Langer has developed multiple drug delivery platforms and established more than 40 startup companies. Iris Zemzoum, representative of Novartis in the Asia-Pacific, Middle East, and Africa-related regions, said these changes include scientific innovation, partnerships, and healthy digital growth.
“During the pandemic, we have continued to work with local stakeholders to help upgrade the domestic biotechnology industry to international standards,” said Herbert Wu, Chairman of the Taiwan Bio Industry Organization (Taiwan BIO).
In addition, under the impact of the global epidemic, cell therapy is growing rapidly. The adult respiratory distress syndrome (ARDS) caused by COVID-19 is as high as 9 million people, prompting global mesenchymal stem cell (MSC) treatment of acute lung injury-related clinical research cases to grow eight times in 18 months.
COVID-19 has caused the world to re-examine medical resources and pay attention to the importance of the biotechnology industry. How to cooperate between countries in the future, how to provide resources to each other, and improve medical technology and research and development capabilities require the biotechnology industry’s assistance.